Investment case

Why should you invest in Enzymatica? 

✓ A solid scientific base and knowledge, verified via in vitro and clinical studies of the ColdZyme Mouth Spray.  

✓ Unique patented product that addresses the cause of colds, while most other cold products only provide symptomatic relief. 

✓ Proven success on the Swedish home market through continual growth since the launch in 2013.  

✓ Scalable business model based on partnerships with successful international distributors with strong market prescence.

Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.